• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Xience V - Leapfrogging To Lead DES Market In The US Product Image

Xience V - Leapfrogging To Lead DES Market In The US

  • Published: May 2008
  • Region: United States
  • 13 pages
  • GlobalData

Xience V - Leapfrogging To Lead DES Market In The US

Summary

GlobalData viewpoints are an essential source of high quality information on all key events in the medical equipment industry. GlobalData viewpoints are typically our opinion on the key events, strategic rationale and its impact on the future outlook of the medical equipment sectors. GlobalData viewpoints cover financial deals and their impact on the competitive landscape, impact of product approvals on existing market segments, emerging technologies and products in develoopment, reimbursement policies and impact on procedure numbers, government policies and reforms to make devices safer and effective through regulatory changes.

Scope

- Viewpoints are a source of real-time and frequent updates on key events in the medical equipment sectors and provide insights on market size (historic and forecast), procedure numbers, pricing trends and competitive landscape
- Viewpoints provide in depth analysis of market drivers, restraints and trends impacting the future of the sectors and sub-sectors
- Viewpoints are analytical alerts that provide information on emerging technologies and products in development READ MORE >

1 2
1.1 List of Figures 4
2 GlobalData Viewpoint 5
2.1 Summary 5
3 Xience V - Leapfrogging to Lead DES Market in the US 6
3.1 Xience’s Success 6
3.1.1 Strong Scientific Basis 6
3.1.2 SPIRIT Trials - Strong Clinical Data Support 6
3.2 Milestones for Xience in 2007 7
3.2.1 Gender Specific Trial 7
3.2.2 Transcatheter Cardiovascular Therapeutics 2007 8
3.2.3 FDA Advisory Committee Recommends Approval of Xience V 8
3.2.4 Xience Gains Reimbursement Approval in France 8
3.3 Outlook and Implications 8
4 Recent Developments 9
4.1 Study in JAMA Shows Patients Treated With Abbotts XIENCE V Drug Eluting Stent Experience Better Outcomes 9
4.1.1 Boston Scientific Receives Canadian Approval for TAXUS Liberte Stent System 9
5 Appendix 10
5.1 Methodology 10
5.1.1 Coverage 10
5.1.2 Secondary Research 11
5.1.3 Primary Research 11
5.1.4 Models 12
5.1.5 Forecasts 12
5.1.6 Expert Panel Validation 13
5.2 Contact Us 13
5.3 About Us 13
5.4 Disclaimer 13

Executive Summary

1.1 List of Figures
Figure 1: Meta-Analysis of 12-Month Data from SPIRIT II and III, 2007 7
Figure 2: GlobalData Methodology 10

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos